ABSTRACT In striated muscle thin filament activation is initiated by Ca 21 binding to troponin C and augmented by strong myosin binding to actin (cross-bridge formation). Several lines of evidence have led us to hypothesize that thin filament properties may limit the level and rate of force development in cardiac muscle at all levels of Ca 21 activation. As a test of this hypothesis we varied the cross-bridge contribution to thin filament activation by substituting 2 deoxy-ATP (dATP; a strong crossbridge augmenter) for ATP as the contractile substrate and compared steady-state force and stiffness, and the rate of force redevelopment (k tr ) in demembranated rat cardiac trabeculae as [Ca 21 ] was varied. We also tested whether thin filament dynamics limits force development kinetics during maximal Ca 21 activation by comparing the rate of force development (k Ca ) after a step increase in [Ca 21 ] with photorelease of Ca 21 from NP-EGTA to maximal k tr , where Ca 21 binding to thin filaments should be in (near) equilibrium during force redevelopment. dATP enhanced steady-state force and stiffness at all levels of Ca 21 activation. At similar submaximal levels of steady-state force there was no increase in k tr with dATP, but k tr was enhanced at higher Ca 21 concentrations, resulting in an extension (not elevation) of the k tr -force relationship. Interestingly, we found that maximal k tr was faster than k Ca , and that dATP increased both by a similar amount. Our data suggest the dynamics of Ca 21 -mediated thin filament activation limits the rate that force develops in rat cardiac muscle, even at saturating levels of Ca 21 .
INTRODUCTION
Striated muscle contraction results from cyclic interactions between myosin and actin, which are regulated by the troponin-tropomyosin complex of the thin filament. Ca 21 binding to the thin filament regulatory protein troponin C (TnC) initiates contraction (Gordon et al., 2000) and the level of force developed is determined by the availability of myosin binding sites on thin filaments, which is ultimately controlled by the distribution of tropomyosin (Tm) between positions on the surface of thin filaments that either block or uncover binding sites on actin for myosin cross-bridge attachment. Transduction of the Ca 21 signal is through the troponin complex, resulting in increased mobility of Tm over the surface of actin and exposure of strong binding sites for myosin. This shifts the thin filament from a ''blocked'' to a ''closed'' state (McKillop and Geeves, 1993) , thereby allowing further myosin cross-bridge formation. Strong cross-bridge binding is then thought to stabilize Tm in an ''open'' state and the thin filament is considered ''activated.'' In effect, the level of contractile activation appears to result from a balance of the effects of Ca 21 binding to TnC and cross-bridges on Tm state. The growing amount of evidence suggests that cross-bridge displacement of Tm into an activating position may play a more prominent role in the regulation of cardiac contraction (Fuchs and Smith, 2001 ).
Like force, the rate of force development is Ca 21 dependent, but the mechanisms that determine the thin filament activation dependence of force kinetics are less well established. In demembranated skeletal muscle fibers the relationship between steady-state force and the rate that force redevelops (k tr ) after a release-restretch cycle is Ca 21 sensitive, being slow (1-2 s ÿ1 at 10-15°C) at low levels of force and increasing 10-15-fold as force rises to maximum at high levels of Ca 21 activation (Brenner, 1986 (Brenner, , 1988 . Based on these and other findings it was suggested that Ca 21 controls the rate-limiting process in force development rather than simply controlling the level of cross-bridge recruitment (Brenner, 1986 (Brenner, , 1988 . However, we and others have shown that in skeletal muscle when the Ca 21 -activated force is high the kinetics of actin-myosin interaction are likely limiting to the rate of force development, whereas at submaximal force the rate-limiting process may be the kinetics of thin filament activation (Chase et al., 1994; Regnier et al., 1996 Fitzsimmons et al., 2001a,b) . This limiting process is greatest at low levels of activation, as most of the increase in k tr comes at Ca 21 concentrations that produce .50% of maximal Ca 21 -activated steady-state force.
Similar to reports for fast skeletal muscle, k tr is Ca 21 dependent in demembranated cardiac muscle. However, most studies have reported smaller magnitude (one-to fivefold) change in k tr (compared with skeletal muscle) as the level of Ca 21 activation is varied (Wolff et al., 1995; Palmer and Kentish, 1998; Patel et al., 2001) , though one recent report suggest a .8-fold change (Fitzsimons et al., 2001) . These studies mostly show that at similar temperatures k tr is similar or faster in cardiac versus skeletal muscle at low Ca 21 concentrations, and slower at high levels of Ca 21 activation. This suggests the lower Ca 21 dependence of k tr results from different actin-myosin cycling kinetics (the main determinant of maximal k tr in skeletal muscle) and/or the relative kinetics of thin filament processes versus actin-myosin cycling kinetics is different than in skeletal muscle (Hancock et al., 1997) . Coupled with evidence that thin filament activation level is more dependent on strong cross-bridge binding in cardiac (versus skeletal) muscle, it also suggests that Ca 21 binding to Tn may result in less complete activation of cardiac thin filaments (Regnier et al., 2000b) .
We have been studying the relative contribution of Ca 21 binding to TnC and cross-bridge binding on both the level of thin filament activation and the rate that force develops in cardiac and skeletal muscle. A particularly successful approach has been to alter cross-bridge binding and cycling rates by using nucleotide analogs of ATP (NTPs) as the substrate for contraction. We have shown that one of these analogs, 2 deoxy-ATP (dATP), has an affinity for skeletal myosin similar to that of ATP and increases both solution NTPase and unloaded shortening velocity of rabbit skeletal and rat cardiac muscle (Regnier and Homsher, 1998; Regnier et al., , 2000b . Interestingly, dATP enhances both maximal Ca 21 -activated steady-state force (F max ) and k tr in cardiac trabeculae from both untreated rats, containing mostly a-MHC (fast cardiac myosin), and PTU-treated rats, containing b-MHC (slow cardiac myosin) (Regnier et al., 2000b) . This contrasts with our findings in skeletal muscle where dATP has no effect on F max , but increases maximal k tr in rabbit psoas fibers (fast skeletal myosin) and rat soleus fibers (slow skeletal myosin) . These results indicate that cross-bridge cycling rate per se cannot explain these cardiac versus skeletal muscle differences, and suggests that the properties of cardiac thin filament regulatory proteins may limit cross-bridge cycling. Therefore we have hypothesized that (compared to ATP) dATP augments the level of thin filament activation and/or strong cross-bridge binding at saturating Ca 21 concentration in demembranated cardiac muscle, resulting in an increase in F max and maximal k tr over that attained with ATP as the contractile substrate. This hypothesis is supported by our finding that dATP also enhances both force and k tr at subsaturating levels of Ca 21 activation in skeletal muscle .
In this study we hypothesized that the relatively low activation dependence of k tr in cardiac muscle (compared with skeletal muscle) reflects a relative limitation of Ca 21 binding to TnC to activate thin filaments at all levels of Ca 21 . Consequently, this would give cross-bridge binding a more prominent role in the activation process. To test this hypothesis we compared steady-state force and stiffness, and k tr in rat cardiac trabeculae as Ca 21 concentration was varied with either 5 mM ATP or 5 mM dATP as the contractile substrate. In addition, we tested the hypothesis that thin filament kinetics can limit the rate of force development during maximal Ca 21 activation. To do this we compared the rate force develops after a step increase in Ca 21 concentration with photorelease of Ca 21 from NP-EGTA (k Ca ) (EllisDavies and Kaplan, 1994) to maximal k tr , where Ca 21 binding to thin filaments should be in (near) equilibrium during force development. We found that dATP enhanced steady-state force and stiffness at all levels of Ca 21 activation. We also found that at similar submaximal levels of steady-state force there was no increase in k tr with dATP, but dATP enhanced k tr at higher Ca 21 concentrations, resulting in an extension (not elevation) of the curvilinear force-k tr relationship. Similar results were obtained for rat trabeculae with either a-MHC or b-MHC isoforms, indicating this effect was not due to the absolute rate of cross-bridge cycling. Significantly, we found that k tr is faster than k Ca with maximal Ca 21 activation, and that both are increased a similar amount by dATP. This finding suggests the kinetics and/or level of Ca 21 -mediated thin filament activation may limit the rate that force develops in rat cardiac muscle, even at saturating levels of Ca 21 . In a subsequent article, (Adhikari et al., 2004) , we show that this property of cardiac thin filaments may at least partially explain the greater sarcomere length-dependence of force found in cardiac (versus skeletal) muscle. Preliminary reports of this work have been published previously (Regnier et al., 2000a; Martin et al., 2002) .
METHODS
Male Sprague-Dawley rats (200-250 grams), either treated with propylthiouracil (PTU; 0.5% added to drinking water for 4-8 weeks) or untreated (as age-matched animals) were euthanized with sodium pentabarbitol (50 mg/ kg). Hearts were excised and the interior wall of the right ventricle exposed to relaxing solution (see below) containing glycerol (50% v/v) and Triton X-100 (1%) overnight at 5°C. Individual trabeculae were dissected and stored at 5°C for up to 4 days. ) was set by adjusting Ca(propionate) 2 . Individual chemically demembranated (''skinned'') trabeculae were wrapped in aluminum foil T-clips for attachment to a force transducer (either Model 400A, 2.2 kHz-resonant frequency (Cambridge Technology, Watertown, MA) or Model AE801, $5 kHz resonant frequency (SensoNor, Horton, Norway)) and a servo-motor (model 300, Cambridge Technology, Watertown, MA) tuned for a 300 ms-step response. For most experiments trabecular sarcomere length (L s ) was measured with helium-neon laser diffraction (Chase et al., 1993) and set to 2.25 mm at pCa 9.2. At this L s trabeculae lengths ranged from 1.2-2.3 mm and diameters averaged 140 6 16 mm, with no significant difference between trabeculae from normal versus PTU-treated rats. Stiffness was determined by small amplitude (0.05% L s ) sinusoidal length oscillations (1 kHz). Steady-state isometric force is reported as kN/M 2 in Results, assuming circular geometry and the rate of isometric tension redevelopment (k tr ) was determined from the halftime of force recovery after a rapid release-restretch transient, as previously described . For comparisons, force and k tr are reported normalized to measurements obtained during maximal Ca 21 activation with ATP as the contractile substrate.
Solutions
Comparisons of maximal k tr with the rate of force development (k Ca ) after photorelease of Ca 21 from NP-EGTA were made during the same activation done in a separate set of experiments under identical conditions, except temperature was 17°C instead of 15°C. k Ca was measured as described in Martin et al. (2004) . Briefly, after initial Ca 21 activations in either ATP or dATP, during which control measurements of k tr were performed at maximal activation (k tr control ), the preparation was transferred through a series of NTP containing solutions to a final photolysis solution containing 5 mM NTP, 2mM NP-EGTA, and ;1.8 mM added calcium. The output from a frequency doubled ruby laser producing ;150 mJ in a 50 ns pulse at a wavelength of 347 nm (Laser Applications, Winter Park, FL) was focused onto the trabeculae. Incident energy was measured by deflecting 10% of the beam energy onto a Scientech Energy Meter (365, Boulder, CO); ;2 s after peak force was attained, k tr was measured (k tr photolysis ) and the tissue relaxed. For these experiments, all elicited transients were collected for subsequent analysis but only those resulting in maximal activations within 5% of maximal Ca 21 -activated force at pCa 4.0 (F max ) have been included in the data.
Data analysis
Force-pCa and k tr -pCa relationships are fit with the Hill equation:
From each Hill fit, the pCa at half-maximal force or k tr (pCa 50 ) and the slope (n H ) are determined, and reported pCa 50 and n H values represent the means of the values from the individual fits, 6 SE. The time course of force development from k tr and k Ca protocols was determined by exponential fits or from t 1/2 values, as previously described in (Chase et al., 1994) , both yielding similar results. Summarized data are reported as mean 6 SE and means were compared using Student's t-test, with significance at the 95% confidence level.
RESULTS

Steady-state force
In chemically demembranated (skinned) trabeculae, substitution of 5 mM dATP for 5 mM ATP increased steadystate force at all levels of Ca 21 activation. The steady-state force data for all the experiments is summarized in Fig. 1 . Trabeculae from untreated and PTU-treated rats were used to determine if force enhancement by dATP depends on the myosin isoforms present. Force values were normalized to F max with ATP for each trabecula and the Ca 21 -dependence of force was characterized from fitting the Hill equation to the data (Eq. 1 in Methods) to obtain 1), the [Ca 21 ] required to elicit half of maximal Ca 21 -activated force (i.e., pCa 50 or Ca 21 sensitivity); and 2), the slope (n H or Hill coefficient) of the steep portion of the force-pCa relationship. For trabeculae from untreated rats F max was 20.0 6 4.2 kN/m 2 with ATP (n ¼ 8) and was increased by 31 6 3% with dATP ( Fig. 1 a) . In trabeculae from PTU-treated rats F max was 17.6 6 4.2 kN/m 2 with ATP (n ¼ 10) and was increased by 39 6 4% with dATP ( Fig. 1 b) . These increases in F max with dATP are similar to what we have previously reported (Regnier et al., 2000b) . dATP increased the Ca 21 -sensitivity of force (pCa 50 ) of trabeculae from both untreated and PTU-treated rats, but had no significant effect on n H . For trabeculae from untreated rats, dATP increased the Ca 21 -sensitivity of force (P , 0.05) by 0.13 pCa units from 5.41 6 0.01 (ATP) to 5.54 6 0.03 (dATP), whereas corresponding n H values were 5.4 6 0.6 (ATP) and 4.6 6 1.2 (dATP). For trabeculae from PTU-treated rats, pCa 50 with ATP was similar to untreated rats, whereas the increase of Ca 21 sensitivity of force with dATP was greater than found for untreated rats, increasing 0.26 pCa units from 5.43 6 0.01 (ATP) to 5.69 6 0.03 (dATP). n H was unaffected by dATP in PTU treated trabeculae (3.2 6 0.2 (ATP) vs. 3.5 6 0.6 (dATP)). The Hill fit parameters (pCa 50 and n H ) for the force-pCa relations for trabeculae from untreated and PTU-treated rats included in Table 1 .
In a subgroup of trabeculae from PTU-treated rats, steadystate stiffness was measured with small amplitude oscillations (see Methods). Linear regression analysis of the stiffness versus force relationship (as Ca 21 was varied) for activations in ATP versus dATP demonstrated a proportional increase in -sensitivity of steady-state force in skinned trabeculae. Force was normalized to maximal force at pCa 4.5 with ATP (d) for trabeculae from normal (a) and PTU-treated (b) rats for comparisons. Data are reported as the mean 6 SE for each pCa. Data were fit to Eq. 1 (Methods) and values for pCa 50 and n H are reported in the text of Results. Fits for the data were r 2 . 0.997.
stiffness versus force for both nucleotides (Fig. 2) . This suggests the increased force with dATP at each pCa results from enhanced strong cross-bridge binding.
Rate of force redevelopment (k tr )
Similar to the results with steady-state force, dATP enhanced k tr at varying levels of Ca 21 activation. The force traces in Fig. 3 show this enhancement for example trabeculae from an untreated (Fig. 3 a) and a PTU-treated (Fig. 3 b) rat during activations at pCa 5.5 and pCa 4.0. In both of these examples trabeculae dATP elevated steady-state force at pCa 5.5 and pCa 4.0 by similar amounts versus ATP, and at pCa 5.5, k tr was approximately doubled whereas maximal k tr (pCa 4.0) was increased by 27 6 5% (untreated) and 47 6 4% (PTUtreated). Fig. 4 summarizes k tr measurements at varying levels of activating Ca 21 , normalized to pCa 4.0 and ATP. At 15°C maximal k tr with ATP was 10.6 6 0.8 s ÿ1 (n ¼ 8) for trabecula from untreated rats and 3.0 6 0.2 s ÿ1 (n ¼ 10) for trabeculae from PTU-treated rats. The data show that dATP increased k tr at higher levels of Ca 21 activation, but had little or no effect on k tr at the lowest levels of activation.
Although the starting level of force after restretch of muscle fibers varied somewhat between preparations and between measurements with ATP versus dATP within the same preparation, there was no indication these variable startingforce levels affected the magnitude differences in k tr between ATP and dATP. Hill fits to the data indicate an increase in the Ca 21 sensitivity (pCa 50 ) of k tr with dATP. In trabeculae from untreated rats (Fig. 4 a) pCa 50 was increased by 0.10 units (P , 0.05) from 5.28 6 0.01 (ATP) to 5.38 6 0.01 (dATP). This increase in the Ca 21 sensitivity of k tr was similar to the increase seen for steady-state force (Fig. 1 a) and stiffness (Fig. 2) . For trabeculae from PTU-treated rats The number of trabeculae used for each NTP condition is given in parentheses. F max and maximal k tr values are normalized to force obtained with 5 mM ATP at pCa 4.5. ( Fig. 4 b) , the pCa 50 of k tr was increased by 0.05 units (P , 0.05) from 5.42 6 0.01 (ATP) to 5.47 6 0.01 (dATP), an increase not as profound as that seen for steady-state force (Fig. 1 b) . These data are included in Table 1 for comparison to the corresponding steady-state force values. The leftward shift observed for both the force versus pCa (Fig. 1) and k tr versus pCa (Fig. 4) relationships suggest that increases in k tr with dATP may have resulted from an increased number of cross-bridges available to participate in the force-generating process. To test this idea, the k tr data in Fig. 4 were replotted as k tr versus force (both normalized to pCa 4.0 with ATP) at each level of Ca 21 in activation solutions (Fig. 5) . This replotting of the data clearly demonstrates that k tr was similar for dATP during Ca 21 -activated contractions producing similar levels of steady-state force and was elevated by dATP only at activation levels resulting in greater steady-state force than that obtained with ATP during maximal Ca 21 activation. When coupled with the stiffness data, which rises proportionally with force (Fig. 2) , it also suggests that k tr with dATP is increased because of a greater recruitment of force generating cross-bridges at each level of activating Ca 21 , including during maximal Ca 21 activation.
Rate of force development (k Ca )
To investigate how Ca 21 activation processes might limit the rate of force development in cardiac muscle we compared the rate of force development under conditions where the [Ca 21 ] is kept constant (k tr ) versus when activation is initiated by a step increase in [Ca 21 ] by laser photolysis of NP-EGTA (k Ca ). Fig. 6 (upper panel) shows an example of the protocol used for these comparisons. This trabecula was placed in a control activation solution (pCa 4.5, 5 mM ATP) to determine F max and maximal k tr (first arrow), then was placed in relaxing solution (pCa 8.0). Next the trabecula was transferred into the NP-EGTA activation solution to allow the caged-Ca 21 to diffuse into the contractile lattice (2-3 min.). At this point the trabecula was activated by photolysis of the NP-EGTA (second arrow) and steady-state force developed, ;2 s later a k tr measurement was made (third arrow) and the trabecula was relaxed. In several preparations the k tr measurement was repeated in control activation solution (not shown) to confirm that photolysis produced maximal Ca 21 -activation conditions. The k Ca / k tr procedure was then repeated for activations with dATP as the contractile substrate (right side of Fig. 6, upper panel ) . The order of NTP testing was varied between preparations. Comparisons of k tr and k Ca were made only for maximal Ca 21 activation and then only if the photolysis of NP-EGTA produced Ca 21 activation within 5% of the force level in control activations. For this example trabecula it is obvious this is the case and that F max was increased by dATP in both control and NP-EGTA activations. Fig. 6 , a-d, shows the k tr and k Ca measurements for ATP at greater resolution and demonstrates two consistent findings: 1), steady-state force and k tr after activation by photolysis of NP-EGTA was similar to control activations; and 2), k Ca was slower than k tr . Fig. 7 shows higher time resolution examples of k Ca and the subsequent k tr force traces comparing activations with ATP versus dATP, demonstrating that both measurements are faster when dATP is the substrate for contraction. The data for all experiments is summarized in Table 2 . The k tr averaged 75% faster than k Ca for ATP and 65% faster for dATP, suggesting that the relative difference between the two measurements is independent of cross-bridge cycling rates. The data also show that dATP increased k tr by 50% and k Ca by 60% over measurements with ATP, suggesting faster cross-bridge cycling (dATP) enhances both rates by a similar mechanism.
DISCUSSION
There are three major findings from this study: 1), altering cross-bridge cycling by substitution of dATP for ATP as the contractile substrate increases the Ca 21 sensitivity of steadystate force (Fig. 1 ) and k tr (Fig. 4) in rat cardiac muscle at 15°C, independent of myosin isoform; 2), both maximal Ca 21 -activated steady-state force and the rate of force development (k tr , k Ca ) can be significantly increased by increased cross-bridge binding and/or cycling rate (Fig. 5) ; and 3), the maximal rate that force develops by a step increase in Ca 21 (k Ca ) is significantly slower than the maximal rate of force redevelopment (k tr ) during activations with saturating levels of Ca 21 . The maximal steady-state force and k tr data agree with previous work in cardiac muscle where we demonstrated that dATP elevates maximal Ca 21 activated force, k tr , unloaded shortening velocity and filament sliding velocity in vitro motility assays (Regnier et al., 2000b) . These studies provide information about how altering cross-bridge cycling influences cross-bridge binding and thin filament activation at submaximal levels of Ca 21 in cardiac muscle. The results also allow us to compare results in cardiac muscle with previous work in fast and slow skeletal muscle, where we have extensively studied the effects of cross-bridge binding and cycling rates versus thin filament dynamics on the Ca 21 activation dependence of steady-state force and force development kinetics (Regnier et al., 1996 (Regnier et al., , 1999 (Regnier et al., , 2000a . Those studies provided strong evidence that thin filament dynamics are limiting to the level and rate of force development in skeletal muscle during submaximal Ca 21 activation.
The existing structural sequences and conservation information for myosin heavy chains offer no explanation about how dATP might increase F max in cardiac muscle, but not in skeletal muscle (Regnier et al., 2000b) . Indeed the increase in F max with dATP may be peculiar to mammalian cardiac muscle in general, as we have also found similar results in chemically demembranated trabeculae from mouse and dog heart (unpublished observations). In previous studies we suggested that dATP might increase the number of forcegenerating cross-bridges during submaximal Ca 21 activation in skeletal muscle and during maximal Ca 21 activation in cardiac muscle (Regnier et al., 2000b) by increasing one or more transition rates associated with crossbridge attachment and force generation while increasing the rate of cross-bridge detachment to a lesser extent. In this article, we now propose this enhanced cross-bridge attachment leads to increased activation, which is apparent at submaximal Ca 21 in both muscle types and in maximal force in cardiac muscle.
Steady-state force
Proportional increases in steady-state force and stiffness were found at all levels of Ca 21 activation with dATP. This apparent increase of thin filament activation could result from recruitment of strongly bound force-generating cross-bridges, from an increase in force per cross-bridge, or both. Since dATP increases cross-bridge cycling rate, it suggests the cross-bridge detachment rate (g app ) is increased, which further implies the rate of strong cross-bridge attachment ( f app ) must increase to a greater extent to provide a higher level of steadystate force and stiffness (Regnier et al., 2000b) . This effect of dATP appears to be partially or completely independent of the overall cross-bridge cycling rate, as there were increases in both maximal force and Ca 21 sensitivity of force for trabeculae from untreated versus PTU-treated rats ( Fig. 1 ; Table 1 ). This suggests the effects of dATP are largely independent of myosin kinetics (Figs. 3 and 4) , implying that enhanced strong cross-bridge binding is the important contribution of dATP to increased activation. Whatever the detailed mechanism of force enhancement by dATP, the net result is an apparent elevation of thin filament activation at all levels of Ca 21 in cardiac muscle with either a-or b-MHC. Interestingly, dATP increased the Ca 21 sensitivity of force (pCa 50 ) for trabeculae with b-MHC twice as much as for trabeculae with a-MHC (0.26 vs. 0.13 pCa units, respectively; Fig. 1 and Table 1 ). This suggests enhanced crossbridge binding and/or cycling rate may improve activation in cardiac muscle with slow myosin. Our steady-state force-pCa results (Fig. 1 ) contrast with those reported by Metzger et al. (1999) in their study of myocytes from untreated versus PTUtreated rats. Although we report no difference in the Ca 21 sensitivity of force (pCa 50 ) for trabeculae from untreated versus PTU-treated rats, they observed a decrease in pCa 50 by 0.17 units with no change in the slope (Metzger et al., 1999) . It is unclear why our results differ, but the focus and novel discovery of our study is that increased cross-bridge binding (with dATP) increases pCa 50 of force for both untreated and PTU-treated trabeculae without changing the apparent cooperativity (n H ) of the force-pCa relationship (Fig. 1) .
In cardiac muscle changes in cross-bridge binding have been shown to increase Ca 21 binding to troponin C (Hofmann and Fuchs, 1987; Wang and Fuchs, 1994; The number of trabeculae used for each NTP condition is given in parentheses. For most trabeculae, k Ca and k tr measurements were made for both ATP and dATP. Gordon, 2001) . Our experiments do not allow us to determine if enhanced Ca 21 sensitivity of force with dATP is correlated with increased Ca 21 binding to troponin C or via Ca 21 -independent increases in strong cross-bridge binding (or both). The increased force at saturating [Ca 21 ], however, is most likely explained by increased cross-bridge binding alone because of proportional increases in trabeculae stiffness. To determine if force enhancement by dATP directly results in a shifting of thin filament toward the ''on'' state will require a more direct measurement of the state of tropomyosin on thin filaments.
Rate of force development (k tr , k Ca )
In this study the Ca 21 sensitivity of k tr was increased with dATP ( Fig. 4; Table 1 ), similar to steady-state force. When k tr was plotted versus the steady-state force produced at varying [Ca 21 ], it was apparent that k tr was similar at force and stiffness levels common to both substrates. However, with dATP both k tr and force rose substantially above maximal levels for ATP for trabeculae from both untreated (Fig. 5 a) and PTU-treated (Fig. 5 b) rats, indicating the effect was independent of cardiac myosin isoforms (Regnier et al., 2000b) . Changes in the force-k tr relationship at high levels of Ca 21 with dATP could result from greater activation of thin filaments by cross-bridges, as suggested by the increased stiffness (Fig. 2) . Evidence for elevation of the rate force develops during submaximal Ca 21 activation by enhanced cross-bridge binding was provided by Fitzsimons et al. (2001) , who found that NEM S-1 binding to thin filaments at submaximal forces raised k tr to levels measured during maximal Ca 21 activations. Since NEM S-1 cross-bridges are strong binding and slowly dissociating, they suggested that thin filaments with bound NEM S-1 were at a much higher activation level than in the absence of NEM S-1 at the same level of submaximal Ca 21 , thus allowing a faster rate of force development. An additional effect of dATP may be directly attributed to a faster rate of cross-bridge cycling with dATP since maximal k tr is the sum of f app 1 g app , both of which could be increased by dATP (Regnier et al., 2000b) . However, the similar effect of dATP on k tr -force relations ( Fig. 5 ; Table 1 ) for trabeculae from untreated (mostly a-MHC) and PTU-treated (b-MHC) rats indicates that cross-bridge cycling rate cannot be the only factor limiting the level and rate of force development in cardiac muscle. If k tr at submaximal levels of activation is limited by the intrinsic acto-myosin NTPase rate of cross-bridges, we should have observed an elevation of k tr at all levels of force. In contrast, Fig. 5 shows similar values of k tr for ATP and dATP at the same level of force and stiffness, imply that a noncross-bridge cycling mechanism is limiting the rate that force can develop. An alternative interpretation of our results would be that the amount of force generated per cross-bridge is enhanced with dATP (compared with ATP). However, our previous observation that maximal Ca 21 -activated force is not elevated by dATP in either fast or slow soleus skeletal muscle fibers argues against this. Slow skeletal fibers contain the same myosin isoform (b-MHC) present in trabeculae from PTUtreated rats, indicating dATP-induced elevation of force does not result from an increased level of force per cross-bridge. This suggests that the elevation of force and k tr by dATP result from cross-bridge dependent enhancement of thin filament activation.
In cardiac muscle the relatively low Ca 21 -activation dependence of k tr (a two-to fivefold change compared with a 10-15-fold change for skeletal muscle) could result from an intrinsically lower acto-myosin ATPase activity at maximal activation or a relative limitation of the level of thin filament activation, even at saturating [Ca 21 ]. The last possibility is supported by the observations that 1), cardiac TnC (cTnC) has a single regulatory Ca 21 -binding site (Johnson et al., 1980 ) compared with the two regulatory Ca 21 -binding site for fast skeletal muscle; 2), cTnC undergoes less and slower conformational change upon Ca 21 -binding than skeletal TnC (Sia et al., 1997; Hazard et al., 1998) ; 3), the Ca 21 induced conformational change associated with TnI interaction is slow for cardiac TnC (perhaps as low as 4-6 s ÿ1 ) (Dong et al., 1996 (Dong et al., , 1997 ; and 4), when cardiac TnC is fully substituted for endogenous TnC in skeletal fibers maximum force is significantly lower (Chase et al., 1994; Morris et al., 2001 ). An additional consideration is that the signal transmission of Ca 21 binding to TnC to tropomyosin could be slow relative to cross-bridge cycling rates, especially at low Ca 21 concentrations. If the level or rate of thin filament activation is limited in cardiac muscle, interventions that elevate thin filament activation might be expected to enhance both maximum force and k tr , as we observe with dATP. We have previously demonstrated that thin filament activation dynamics are rate limiting to force development at low levels of Ca 21 in skeletal fibers (Chase et al., 1994; . We now suggest this mechanism may also apply to cardiac muscle.
This hypothesis is further supported by comparisons of k tr and k Ca during the same activation of trabeculae at pCa 4.5. For both ATP and dATP k Ca was consistently only about half as fast as k tr (Table 2, Figs. 6 and 7), indicating the dynamics of thin filament activation by Ca 21 limit the rate of force development. However, because force develops from different levels during k tr and k Ca measurements, differences in time courses of force rise could be influenced by the distribution of compliance between cross-bridges and noncross-bridge components (Huxley et al., 1994; Luo et al., 1994; Higuchi et al., 1995; Martyn et al., 2002) . Comparison of the force traces in Fig. 7 indicates that the k tr force redevelops from a nonzero value, whereas it rises from relaxed levels after the Ca 21 transient. As a result, in k tr measurements the compliance of noncross-bridge structures would be high relative to cross-bridge compliance at the beginning of force development, resulting in an apparent slowing of force kinetics (Luo et al., 1994; Martyn et al., 2002) and thus would underestimate the difference between k tr and k Ca . In comparison, during k Ca measurements noncross-bridge compliance would be lowest at the beginning of force rise, thus the initial rate of force development would be faster, slowing as cross-bridge compliance decreases with increasing force. However, there was no indication of an initial rapid rise of force that approached k tr during k Ca measurements. Thus differences in distribution of compliance between crossbridge and noncross-bridge components do not explain the different time course of k tr and k Ca .
If cross-bridge cycling kinetics were limiting the rate of force development, we would expect k Ca and k tr to be similar. The thin filament activation state should be in near equilibrium during tension redevelopment with the k tr protocol. Changes in myoplasmic [Ca 21 ] during tension transients (Vandenboom et al., 1998; Wang and Kerrick, 2002) or Ca 21 binding when force is inhibited in cardiac muscle (Wang and Fuchs, 1994; Martyn and Gordon, 2001) indicate that some Ca 21 dissociates from thin filaments during the release-restretch transients of k tr measurements. However, this amount is likely to be a small fraction of Ca 21 bound to troponin C at pCa 4.5 (Martyn and Gordon, 2001 ). Furthermore, any thin filament deactivation during the release phase of the release-restretch transient would lead to a slower value of maximal k tr , and thus underestimate differences between k tr and k Ca . In contrast, force development during the k Ca measurement begins with near zero levels of Ca 21 bound to thin filaments. Thus our observation that k Ca is always slower than k tr supports a hypothesis that thin filament activation by Ca 21 is rate limiting for force development even at saturating [Ca 21 ]. Previously Palmer and Kentish (1998) reported no difference between k act (reported here as k Ca ) and k tr in rat and guinea pig trabeculae at 22°C. However these measurements were not obtained during the same activation and may have been from separate trabeculae. Additionally, their k act values in rat trabeculae varied almost fourfold with some activations producing more force than the control activations, and maximum k tr varied by more than twofold. This suggests some of their measurements may have been made in submaximally activating conditions. The argument that thin filament regulatory protein dynamics limit the rate that force develops in cardiac muscle is further supported by the observation that both rates were elevated ;60% by dATP, whereas k Ca remained slower than k tr (Table 1) . Thus, even though cross-bridge cycling kinetics can be increased by dATP, the kinetics of thin filament activation by Ca 21 may limit the rate force develops in rat cardiac muscle. If so, mechanisms that enhance cross-bridge binding at a given submaximal level of intracellular Ca 21 , such as phosphorylation of myosin-binding protein C could be important in increasing the power output of the heart during sympathetic stimulation. This mechanism would not be available to skeletal muscle, where Ca 21 binding to TnC appears to be much more successful in fully activating thin filaments and where contraction usually results from action potential trains that allow muscles to contract at the upper end of the forcepCa relationship.
